HEALTH TECHNOLOGY

Perimeter Medical Imaging AI Announces Commercial Placement of Perimeter S-Series OCT within National Healthcare Provider System

Perimeter Medical Imaging AI, Inc. | September 30, 2022 | Read time : 01:00 min

Perimeter Medical

Perimeter Medical Imaging AI, Inc. announced the commercial placement of its flagship Perimeter S-Series OCT system at a hospital that is part of a major national healthcare system and one of the largest healthcare networks in North Texas. Perimeter is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs.

This commercial placement of our Perimeter S-Series OCT system at a hospital in a major healthcare network marks a significant milestone for us as we gain traction validating our commercial model. Perimeter S-Series OCT aims to improve patient outcomes and lower healthcare costs, and we are excited that leading surgeons and hospitals are seeing the potential of our ground-breaking technology.”

Jeremy Sobotta, Perimeter’s Chief Executive Officer

About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level, with 10x greater image resolution than X-ray and ultrasound, and 100x greater than MRI. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company’s ticker symbol “PINK” is a reference to the pink ribbons displayed during Breast Cancer Awareness Month.

Spotlight

The healthcare industry faces a myriad of challenges and opportunities in 2019. To assist planners, B.E. Smith offers its annual Healthcare Leadership Intelligence Report presenting key findings from a survey of hundreds of executives representing a cross-section of C-suite, senior, and mid-level leaders. Survey topics covered Industry Directions, Career Factors, Talent Management, and Leadership. Analysis of the data and independent research produced 11 influential trends likely to dominate 2019.

Spotlight

The healthcare industry faces a myriad of challenges and opportunities in 2019. To assist planners, B.E. Smith offers its annual Healthcare Leadership Intelligence Report presenting key findings from a survey of hundreds of executives representing a cross-section of C-suite, senior, and mid-level leaders. Survey topics covered Industry Directions, Career Factors, Talent Management, and Leadership. Analysis of the data and independent research produced 11 influential trends likely to dominate 2019.

Related News

HEALTH TECHNOLOGY

WELL Health to Acquire EMR, Billing and Clinical Assets from CloudMD

WELL Health Technologies Corp. | October 12, 2022

WELL Health Technologies Corp. a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce it has entered into an agreement to acquire Cloud Practice Inc. and three clinics from CloudMD Software & Services Inc. "This transaction demonstrates our dedication to expanding and strengthening WELL's Canadian healthcare offering through disciplined capital allocation. This acquisition will also enable our EMR and billing divisions to enter new markets in the Canadian Prairies where we look forward to supporting healthcare practitioners' access to new digital health innovations." Hamed Shahbazi, CEO and Founder of WELL Cloud Practice is a medical software application company with products including Juno EMR, a cloud based EMR solution based on OSCAR1, and ClinicAid, a medical billing software used by healthcare practitioners who don't need access to a full EMR. Outside of WELL who is the largest provider of OSCAR1 EMR products and services, Juno EMR represented the largest remaining asset and market share available in the OSCAR1 based EMR industry. Both Juno EMR and ClinicAid represent WELL's entrance into the Alberta and Saskatchewan markets for its EMR and medical billing related lines of business. Both assets will be integrated into WELL's Provider Solutions Business Unit, under WELL's existing EMR and Billing platforms. Amir Javidan, COO of WELL commented, "This transaction is a win for healthcare practitioners and their patients as it will allow software users and clinicians joining our network to have access to WELL's innovative Apps.Health platform which includes dozens of apps designed by leading 3rd party digital health companies providing advanced physician tools such as an AI-powered virtual assistant to premium digital patient engagement tools that can drive significant operating efficiencies for clinics." The three primary care clinics being acquired in the Transaction currently have a total staff of 20 physicians operating out of two clinics in Vancouver, BC and one clinic in Surrey, BC. These clinics are owned by subsidiaries of CloudMD, with all of the shares of these entities being acquired as part of the Transaction. These three clinics will be integrated into WELL's existing primary care clinic network under WELL Health Canada Clinics Inc. About WELL Health Technologies Corp. WELL is a practitioner focused digital healthcare company whose overarching objective is to positively impact health outcomes to empower and support healthcare practitioners and their patients. WELL has built an innovative practitioner enablement platform that includes comprehensive end to end practice management tools inclusive of virtual care and digital patient engagement capabilities as well as Electronic Medical Records (EMR), Revenue Cycle Management (RCM) and data protection services. WELL uses this platform to power healthcare practitioners both inside and outside of WELL's own omni-channel patient services offerings. As such, WELL owns and operates Canada's largest network of outpatient medical clinics serving primary and specialized healthcare services and is the provider of a leading multi-national, multi-disciplinary telehealth offering. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and on OTCQX under the symbol "WHTCF".

Read More

HEALTH TECHNOLOGY

Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial

Novartis Pharma AG | September 19, 2022

Sandoz, a global leader in off-patent medicines, announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab. “Biosimilars have the opportunity to create a substantial positive impact on patient access and healthcare systems sustainability. Therefore, this important milestone means that we are one step closer to giving individuals living with osteoporosis access to a more affordable, biosimilar version of this critical medicine, which may help to change the course of their disease.” Florian Bieber, Global Head of Development, Sandoz Biopharmaceuticals Denosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal related complications in cancer that has spread to the bone, and giant cell tumor of the bone2,3,4,5. The results from the integrated Phase I/III study confirm the biosimilar matches the reference medicine in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in the respective indications; and contributes to demonstration of similarity, which is the basis for use in all indications. Approximately 500 million men and women worldwide may be affected by osteoporosis1, which causes 8.9 million fractures annually – or one fracture every three seconds1. By 2050, hip fractures are projected to increase by 240% in women and 310% in men compared to 19901. The results come soon after Sandoz confirmed acceptance of license applications for two other proposed biosimilars. In July 2022, the application for the first-of-a-kind multiple sclerosis proposed biosimilar natalizumab was accepted for review by the US Food and Drug Administration (FDA) and European Medicines Agency. In June 2022, the EMA and FDA accepted for review Sandoz applications for the high-concentration formulation 100 mg/mL (HCF) of its biosimilar adalimumab. Sandoz biosimilars help patients, in areas including immunology, oncology, nephrology, supportive care and endocrinology, access critical and potentially life-changing medicines sustainably and affordably. Sandoz has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. About ROSALIA6 In ROSALIA, 527 postmenopausal women with osteoporosis were randomized to receive either biosimilar denosumab or the reference medicine for up to 78 weeks of treatment. Objectives were to demonstrate similar efficacy in terms of change in lumbar spine bone mineral density, as well as similar pharmacokinetics and pharmacodynamics. The global clinical program for biosimilar denosumab was developed in consultation with major regulatory agencies and the results from this clinical study are expected to support regulatory approval. About denosumab Denosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone tissue)2. By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in a reduction of bone loss, and subsequently the likelihood of fractures and other serious bone conditions2.

Read More

FUTURE OF HEALTHCARE

CareView Communications Executes Agreement with New Hospital in Pensacola, FL

CareView Communications, Inc. | November 17, 2022

CareView Communications, Inc. an information technology provider to the healthcare industry, announced the signing of an agreement with a health system building a new campus in Pensacola, FL. The new campus includes a new acute care hospital and behavioral health unit with room for future expansion. The agreement calls for the installation of the CareView Patient Safety System®, which facilitates continuous remote patient monitoring for patients who may be at risk of harm due to falls, behavioral issues, or suicidal ideation. The CareView solution leverages an in-room camera with audio capabilities and patented Virtual Bed Rails® and Virtual Chair Rails® technologies to improve patient safety. The Virtual Rails use machine learning to identify when the patient's movement indicates a fall may be imminent, and subsequently alerts the Safety Technician. Pre-recorded messages or 2-way audio allow for direct communication with the patient. The System offers a considerable impact on sitter reduction and overall patient safety. “We are pleased to be working with our newest partner and know that our System is the solution to address their needs to reduce patient falls and increase patient safety.” Sandra McRee, CareView’s Chief Operating Officer About CareView Communications, Inc. As a leader in turnkey patient video monitoring solutions, CareView is redefining the standard of patient safety in hospitals and healthcare facilities across the country. For over a decade, CareView has relentlessly pursued innovative ways to increase patient protection, providing next-generation solutions that lower operational costs and foster a culture of safety among patients, staff, and hospital leadership. With installations in more than 150 hospitals, CareView has proven that its innovative technology is creating a culture of patient safety where patient falls have decreased by 80% with sitter costs reduced by more than 65%. Anchored by the CareView Patient Safety System, this modular, scalable solution delivers flexible configurations to fit any facility while significantly increasing patient safety and operational savings. All configurations feature HD cameras, high-fidelity 2-way audio/video, LCD displays for the ultimate in capability, flexibility, and affordability. Corporate offices are located at 405 State Highway 121 Bypass, Suite B-240, Lewisville, TX 75067.

Read More